Medi Caps Ltd (MEDICAPS) — shareholding pattern, promoter holding, financials and share price
About Medi Caps Ltd (MEDICAPS)
Medi Caps Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as MEDICAPS and on the BSE under scrip code 523144. Its ISIN is INE442D01010.
Incorporated in 1983, Medi-Caps Ltd is in the business of real estate and pharmaceuticals [1]
Medi-caps Ltd., founded in 1983, is the second-largest manufacturer of empty hard gelatine capsules in India, serving major pharmaceutical companies for oral medications.
The company achieved notable manufacturing milestones, including zero-defect production and full operation normalization, reflecting its industry expertise and quality control.
Listed peers in Pharmaceuticals: Roopa Industries Ltd, JFL Life Sciences Ltd, Parmax Pharma Ltd, Walpar Nutritions Ltd, Welcure Drugs & Pharmaceuticals Ltd, Sunrest Lifescience Ltd.
Valuation & Returns
10 Jul 2026At ₹26.65 a share on 10 Jul 2026, Medi Caps Ltd (MEDICAPS) was valued at a price-to-earnings ratio of -10.94x against an industry P/E of 36.41x and a price-to-book of 0.27x on a book value of ₹97.26 per share as of Mar 2025. Solomo computes return on equity of -2.51% and return on capital employed of -2.48% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- -10.94x
- Industry P/E
- 36.41x
- P/B
- 0.27x
- EPS (TTM)
- ₹-2.44
- Book value / share
- ₹97.26
- ROE
- -2.51%
- ROCE
- -2.48%
- ROA
- -2.42%
- Debt / equity
- 0x
- Dividend yield
- 0%
- EBITDA margin
- -9.6%
- 52-week range
- ₹21 – ₹46.99
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Medi Caps Ltd (MEDICAPS) reported revenue of ₹12.45 crore, net profit of ₹-3.04 crore and earnings per share of ₹-2.44. That compares with revenue of ₹25.48 crore and net profit of ₹-0.57 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹3.45 crore and net profit ₹3.04 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 69.87 | 49.37 | 27.35 | 25.48 | 12.45 |
| Net profit (₹ cr) | 10.08 | 1.76 | -2.24 | -0.57 | -3.04 |
| EPS (₹) | 8.08 | 1.41 | -1.8 | -0.46 | -2.44 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | -23.75% | -28.48% | - | -6.84% |
| Profit growth | -8.06% | - | - | 74.55% |
| Stock price CAGR | 2% | -10% | -11% | -38% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 51.44% of Medi Caps Ltd (MEDICAPS) (up 0.08 pp QoQ) and domestic institutional investors (DII) hold 0.02%. Market capitalisation was ₹33 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: SANGEETHA S 5.55%, DHEERAJ KUMAR LOHIA 4.73%, HUF 2.6%, SONAL LOHIA 1.42%, MANJU GAGGAR 1.1%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 51.44% | - | - | 0.02% | 48.56% |
| Mar 2026 | 51.36% | - | - | 0.02% | 48.64% |
| Dec 2025 | 50.76% | - | - | 0.02% | 49.24% |
| Sep 2025 | 50.77% | - | - | 0.03% | 49.23% |
| Jun 2025 | 50.77% | - | - | 0.03% | 49.23% |
| Mar 2025 | 50.77% | - | - | 0.03% | 49.23% |
| Dec 2024 | 50.62% | - | - | 0.03% | 49.38% |
| Sep 2024 | 50.43% | - | - | 0.03% | 49.57% |